Dr. Chae-Yong Kim from Seoul National University Bundang Hospital recently presented interim data on 10 patients at a medical conference. The presentation highlighted a manageable safety profile, with some patients showing extended disease control and inhibition of tumor recurrence. The study took place in Seongnam and Seoul, South Korea.